{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:48:41Z","timestamp":1792792121780,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To analyze real-world Food and Drug Administration Adverse Event Reporting System (FAERS) data for retinal vasculitis associated with approved intravitreal (IVT) anti-VEGF agents and complement inhibitors in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This retrospective study used the publicly available FAERS database to identify serious adverse events related to IVT anti-VEGF and complement inhibitor agents reported between January 2020 and December 2025. Reports for brolucizumab, faricimab, aflibercept, ranibizumab, pegcetacoplan, and avacincaptad pegol were analyzed, with data for aflibercept and ranibizumab also reviewed from 2010 to 2019. Events were filtered to include only those linked exclusively to a single agent. Retinal vasculitis adverse events (RVAEs) were identified using broad search terms related to vasculitis, while vascular occlusions without inflammation were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>FAERS data from January 2010 to December 2025 showed reported RVAEs across all included IVT therapies, with increased reporting after 2019. From January 2020 to December 2025, 554 RVAEs were identified among anti-VEGF reference products and complement inhibitors. Anti-VEGF reference products accounted for 485 reports (87.5%), and complement inhibitors accounted for 69 (12.5%). Brolucizumab accounted for the largest proportion (56.1%; 311\/554), followed by faricimab (16.4%; 91\/554), pegcetacoplan (11.9%; 66\/554), aflibercept 2 mg (8.7%; 48\/554), aflibercept 8 mg (4.2%; 23\/554), ranibizumab (2.2%; 12\/554), and avacincaptad pegol (0.5%; 3\/554). Separate biosimilar analysis identified one aflibercept biosimilar RVAE and no ranibizumab biosimilar RVAEs during this updated study period overall.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>FAERS reporting identified RVAEs across included IVT therapies, but cannot establish incidence, causality, or comparative risk, underscoring the need for vigilant reporting and ongoing post-marketing safety surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004980","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:00:46Z","timestamp":1787320846000},"page":"2004-2011","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["REAL-WORLD RETINAL VASCULITIS EVENTS REPORTED WITH FDA-APPROVED INTRAVITREAL ANTI-VEGF AND COMPLEMENT INHIBITOR AGENTS"],"prefix":"10.1097","volume":"46","author":[{"given":"Jay","family":"Chhablani","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraya","family":"Nayaka","sequence":"additional","affiliation":[{"name":"The Eye Foundation, Coimbatore, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Sadeghi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"B","sequence":"additional","affiliation":[{"name":"Independent Ophthalmology Medical Affairs and Clinical Development Consultant"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261020","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"Am J Pathol"},{"key":"R2-20261020","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.2147\/OPTH.S489114","article-title":"Outcomes of anti-VEGF therapy in eyes with diabetic macular edema, vein occlusion-related macular edema, and neovascular age-related macular degeneration: a systematic review","volume":"18","author":"Aldokhail","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"R3-20261020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/08820538.2023.2271095","article-title":"Safety and efficacy of brolucizumab in the treatment of diabetic macular edema and diabetic retinopathy: a systematic review and meta-analysis","volume":"39","author":"Abu Serhan","year":"2024","journal-title":"Semin Ophthalmol"},{"key":"R4-20261020","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/aos.17506","article-title":"Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: a systematic review with network meta-analysis","volume":"103","author":"Butler","year":"2025","journal-title":"Acta Ophthalmol"},{"key":"R5-20261020","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.survophthal.2025.05.008","article-title":"Effectiveness and safety of anti-vascular endothelial growth factor therapies for macular edema in retinal vein occlusion: a systematic review and network meta-analysis of randomized controlled trials","volume":"70","author":"Chen","year":"2025","journal-title":"Surv Ophthalmol"},{"key":"R6-20261020","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s40123-025-01144-9","article-title":"Clinical outcomes of treatment of geographic atrophy: a narrative review","volume":"14","author":"Nissen","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"R7-20261020","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/24741264251332515","article-title":"Intraocular inflammation, safety events, and outcomes after intravitreal injection of ranibizumab, aflibercept, brolucizumab, abicipar pegol, and faricimab for nAMD","volume":"9","author":"Stevanovic","year":"2025","journal-title":"J Vitreoretin Dis"},{"key":"R8-20261020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/02713683.2024.2402319","article-title":"Effect modifiers and risk factors of intraocular inflammation following brolucizumab: a systematic review and meta-analysis","volume":"50","author":"Abu Serhan","year":"2025","journal-title":"Curr Eye Res"},{"key":"R9-20261020","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with Brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mones","year":"2021","journal-title":"Ophthalmology"},{"key":"R10-20261020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IIO.0000000000000580","article-title":"Sterile intraocular inflammation following intravitreal injections: pathogenesis, clinical features, and management","volume":"65","author":"Bagheri","year":"2025","journal-title":"Int Ophthalmol Clin"},{"key":"R11-20261020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson","year":"2021","journal-title":"Int J Retina Vitreous"},{"key":"R12-20261020","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of Brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"},{"key":"R13-20261020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/24741264231220224","article-title":"Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee","volume":"8","author":"Witkin","year":"2024","journal-title":"J VitreoRetinal Dis"},{"key":"R14-20261020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/0975-1483.66802","article-title":"Pharmacovigilance: a worldwide master key for drug safety monitoring","volume":"2","author":"Jeetu","year":"2010","journal-title":"J Young Pharm"},{"key":"R15-20261020","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"R16-20261020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R18-20261020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.oret.2020.09.020","article-title":"Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after Brolucizumab treatment","volume":"5","author":"Baumal","year":"2021","journal-title":"Ophthalmol Retina"},{"key":"R19-20261020","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ophtha.2024.08.022","article-title":"MERLIN: two-year results of brolucizumab in participants with neovascular age-related macular degeneration and persistent retinal fluid","volume":"132","author":"Brown","year":"2025","journal-title":"Ophthalmology"},{"key":"R20-20261020","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with faricimab","volume":"142","author":"Cozzi","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"R21-20261020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10384-024-01107-w","article-title":"Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration","volume":"68","author":"Matsumoto","year":"2024","journal-title":"Jpn J Ophthalmol"},{"key":"R22-20261020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/24741264231220224","article-title":"Retinal vasculitis after intravitreal Pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee","volume":"8","author":"Witkin","year":"2024","journal-title":"J Vitreoretin Dis"},{"key":"R23-20261020","doi-asserted-by":"crossref","first-page":"1521358","DOI":"10.3389\/fphar.2025.1521358","article-title":"Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database","volume":"16","author":"He","year":"2025","journal-title":"Front Pharmacol"},{"key":"R24-20261020","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/09273948.2025.2476061","article-title":"Increased risk of retinal vasculitis may be associated with aflibercept 8 mg: a pharmacovigilance analysis of the FAERS database","volume":"33","author":"Nowroozzadeh","year":"2025","journal-title":"Ocul Immunol Inflamm"},{"key":"R25-20261020","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ajo.2025.04.022","article-title":"Ocular adverse events associated with pegcetacoplan and avacincaptad pegol for geographic atrophy: a population-based pharmacovigilance study","volume":"276","author":"Kailani","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"R31-20261020","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/ICU.0000000000000869","article-title":"The American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight): current and future state of big data analytics","volume":"33","author":"Pershing","year":"2022","journal-title":"Curr Opin Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:00:24Z","timestamp":1792530024000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/IAE.0000000000004980"}},"subtitle":["An Analysis of FAERS Data"],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004980","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11]]}}}